NCT00106002View on ClinicalTrials.gov

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Breast CancerBreast Neoplasms, MaleCarcinoma, Ductal
Interventions
DRUG

pemetrexed

600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression

Trial Locations (1)

75204

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00106002 - Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter